Topic
Pharmaceuticals
1,010 published works
China Law Insight
Enforcing Medical-Use Patents in China – Challenges and Insights
By King & Wood
Authored by: GORDON GAO and Yao Xiaoyi (Sherry) In recent years, China has become an increasingly important jurisdiction for pharmaceutical patent protection, including patents covering the medical use of known…
China Law Insight
医药反垄断合规——首例未达申报标准禁止集中案评析
By King & Wood
作者:宁宣凤 柴志峰 吴炜旻 张英伦 马骁 赵飞燕 2025年7月23日,国家市场监督管理总局发布关于禁止W医药公司收购S制药公司股权案反垄断审查决定的公告(《公告》)。该案的股权收购协议签订于2018年11月,后于2019年3月完成股权变更登记。《公告》称,交易方在集中协议签署的上一年度2017年中国境内营业额均低于8亿元人民币,即未达到2024年修订后的《国务院关于经营者集中申报标准的规定》,但市场监管总局认为交易具有或者可能具有排除、限制竞争效果,于2025年1月要求W医药公司及其最终控制人进行申报。 阅读更多
GoodLifeSci
EU Pharma Review: Trilogue negotiations under the shadow of U.S. MFN pricing
By Maarten Meulenbelt, Josefine Sommer, Dr. Chris Boyle, Zina Chatzidimitriadou
The coming months will be crucial for the so-called “Pharma Package”, the largest revision of EU pharmaceutical law since 1965. So-called “trilogue” negotiations are being held between the European Commission…
Drug & Device Law
“Rapid Release” Class Action Dissolved
By Bexis
Plaintiffs (or more properly, their lawyers) across the country have been filing no-injury class actions against over-the-counter (“OTC”) drug manufacturers on a variety of cooked-up theories that have little or…
Big Molecule Watch
Alteogen’s Aflibercept Biosimilar Receives Positive CHMP Opinion
We previously reported that South Korean biopharmaceutical company Alteogen submitted its Marketing Authorization Application to the European Medicines Agency (“EMA”) for ALT-L9, what has since been named EYLUXVI. EYLUXVI is…
Government Contracts Law
Making Hay of the Interplay Between the TAA and BAA—COFC Sustains Protest Against the VA’s Improper Sourcing of a Critical Pharmaceutical
On July 31, 2025, the Court of Federal Claims (COFC) issued its decision in The DaVinci Company v. United States. The case is noteworthy for contractors grappling with geographical supply…
Intellectual Property Law Blog
Claiming A Range, Watch Out For The Presumption Of Obviousness
This Federal Circuit opinion analyzes the presumption of obviousness and the obviousness challenge based on prior art that describes a wider range of doses than what is claimed. Background Janssen…
Regulatory Oversight
State AGs Join $202M Settlement Over HIV Drug Kickback
By Troutman Pepper Locke State Attorneys General Team, Timothy Shyu
What Happened On July 16, 49 attorneys general (AGs) announced that they joined a $202 million settlement with Gilead Sciences, Inc. (Gilead). Previously announced by the Department of Justice in…
BioSlice Blog
EU Consults on New GMP Rules for AI in Pharma Manufacturing
By Alexander Roussanov, Anna Pothof
On 7 July 2025, the European Commission launched a public consultation that could mark the start of a turning point for how Artificial Intelligence (AI) is used in pharmaceutical manufacturing.…
Ogden Glazer + Schaefer Blog
Say Hello to Our New Law Clerk!
By Erin Ogden
Sean McArthur has joined the OG+S team as a law clerk. He brings a background in regulatory compliance, pharmaceutical operations, and surgical hospital administration—plus a flair for storytelling that somehow…